Dr Laura Riva | Principal Bioinformatician

Riva, Laura

Laura is currently studying mutational signatures of cancer development in mice which have been exposed to known or suspected carcinogens.

My main aim is to use and develop computational approaches to analyse and interpret cancer genomes. I am interested in identifying somatic mutations, driver genes and in understanding the biological mechanisms underlying mutational processes. 

I have previously implemented computational methods to identify cancer driver genes and putative cancer predisposing genes. In addition, I have contributed to the identification of genes essential for tumour growth by using in vivo genetic screens of patient-derived tumours. As a postdoctoral fellow, I developed systems biology approaches to integrate -omics data to identify active pathways and to study regulatory networks in neurodegenerative disorders.
 

Publications

  • A knowledge-based framework for the discovery of cancer-predisposing variants using large-scale sequencing breast cancer data.

    Melloni GEM, Mazzarella L, Bernard L, Bodini M, Russo A et al.

    Breast cancer research : BCR 2017;19;1;63

  • In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer.

    Carugo A, Genovese G, Seth S, Nezi L, Rose JL et al.

    Cell reports 2016;16;1;133-147

  • In Vivo Genetic Screens of Patient-Derived Tumors Revealed Unexpected Frailty of the Transformed Phenotype.

    Bossi D, Cicalese A, Dellino GI, Luzi L, Riva L et al.

    Cancer discovery 2016;6;6;650-63

  • Peak shape clustering reveals biological insights.

    Cremona MA, Sangalli LM, Vantini S, Dellino GI, Pelicci PG et al.

    BMC bioinformatics 2015;16;349

  • DOTS-Finder: a comprehensive tool for assessing driver genes in cancer genomes.

    Melloni GE, Ogier AG, de Pretis S, Mazzarella L, Pelizzola M et al.

    Genome medicine 2014;6;6;44

  • The hidden genomic landscape of acute myeloid leukemia: subclonal structure revealed by undetected mutations.

    Bodini M, Ronchini C, Giacò L, Russo A, Melloni GE et al.

    Blood 2015;125;4;600-5

  • Poly-glutamine expanded huntingtin dramatically alters the genome wide binding of HSF1.

    Riva L, Koeva M, Yildirim F, Pirhaji L, Dinesh D et al.

    Journal of Huntington's disease 2012;1;1;33-45

  • Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups.

    Riva L, Ronchini C, Bodini M, Lo-Coco F, Lavorgna S et al.

    Blood cancer journal 2013;3;e147

  • Insights into GATA-1-mediated gene activation versus repression via genome-wide chromatin occupancy analysis.

    Yu M, Riva L, Xie H, Schindler Y, Moran TB et al.

    Molecular cell 2009;36;4;682-95

  • Bridging high-throughput genetic and transcriptional data reveals cellular responses to alpha-synuclein toxicity.

    Yeger-Lotem E, Riva L, Su LJ, Gitler AD, Cashikar AG et al.

    Nature genetics 2009;41;3;316-23

  • No unexpected CRISPR-Cas9 off-target activity revealed by trio sequencing of gene-edited mice.

    Iyer V, Boroviak K, Thomas M, Doe B, Riva L et al.

    PLoS genetics 2018;14;7;e1007503

  • PML-RARA-associated cooperating mutations belong to a transcriptional network that is deregulated in myeloid leukemias.

    Ronchini C, Brozzi A, Riva L, Luzi L, Gruszka AM et al.

    Leukemia 2017;31;9;1975-1986

  • Mutations targeting the coagulation pathway are enriched in brain metastases.

    Richichi C, Fornasari L, Melloni GEM, Brescia P, Patanè M et al.

    Scientific reports 2017;7;1;6573

  • A knowledge-based framework for the discovery of cancer-predisposing variants using large-scale sequencing breast cancer data.

    Melloni GEM, Mazzarella L, Bernard L, Bodini M, Russo A et al.

    Breast cancer research : BCR 2017;19;1;63

  • RNAi screens identify CHD4 as an essential gene in breast cancer growth.

    D'Alesio C, Punzi S, Cicalese A, Fornasari L, Furia L et al.

    Oncotarget 2016;7;49;80901-80915

  • In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer.

    Carugo A, Genovese G, Seth S, Nezi L, Rose JL et al.

    Cell reports 2016;16;1;133-147

  • In Vivo Genetic Screens of Patient-Derived Tumors Revealed Unexpected Frailty of the Transformed Phenotype.

    Bossi D, Cicalese A, Dellino GI, Luzi L, Riva L et al.

    Cancer discovery 2016;6;6;650-63

  • LowMACA: exploiting protein family analysis for the identification of rare driver mutations in cancer.

    Melloni GE, de Pretis S, Riva L, Pelizzola M, Céol A et al.

    BMC bioinformatics 2016;17;80

  • Peak shape clustering reveals biological insights.

    Cremona MA, Sangalli LM, Vantini S, Dellino GI, Pelicci PG et al.

    BMC bioinformatics 2015;16;349

  • INSPEcT: a computational tool to infer mRNA synthesis, processing and degradation dynamics from RNA- and 4sU-seq time course experiments.

    de Pretis S, Kress T, Morelli MJ, Melloni GE, Riva L et al.

    Bioinformatics (Oxford, England) 2015;31;17;2829-35

  • Whole exome sequencing identifies driver mutations in asymptomatic computed tomography-detected lung cancers with normal karyotype.

    Belloni E, Veronesi G, Rotta L, Volorio S, Sardella D et al.

    Cancer genetics 2015;208;4;152-5

  • The hidden genomic landscape of acute myeloid leukemia: subclonal structure revealed by undetected mutations.

    Bodini M, Ronchini C, Giacò L, Russo A, Melloni GE et al.

    Blood 2015;125;4;600-5

  • The genomic and epigenomic landscapes of AML.

    Mazzarella L, Riva L, Luzi L, Ronchini C and Pelicci PG

    Seminars in hematology 2014;51;4;259-72

  • Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups.

    Riva L, Ronchini C, Bodini M, Lo-Coco F, Lavorgna S et al.

    Blood cancer journal 2014;4;e195

  • DOTS-Finder: a comprehensive tool for assessing driver genes in cancer genomes.

    Melloni GE, Ogier AG, de Pretis S, Mazzarella L, Pelizzola M et al.

    Genome medicine 2014;6;6;44

  • Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups.

    Riva L, Ronchini C, Bodini M, Lo-Coco F, Lavorgna S et al.

    Blood cancer journal 2013;3;e147

  • Genomics of acute myeloid leukemia: the next generation.

    Riva L, Luzi L and Pelicci PG

    Frontiers in oncology 2012;2;40

  • Poly-glutamine expanded huntingtin dramatically alters the genome wide binding of HSF1.

    Riva L, Koeva M, Yildirim F, Pirhaji L, Dinesh D et al.

    Journal of Huntington's disease 2012;1;1;33-45

  • Insights into GATA-1-mediated gene activation versus repression via genome-wide chromatin occupancy analysis.

    Yu M, Riva L, Xie H, Schindler Y, Moran TB et al.

    Molecular cell 2009;36;4;682-95

  • Bridging high-throughput genetic and transcriptional data reveals cellular responses to alpha-synuclein toxicity.

    Yeger-Lotem E, Riva L, Su LJ, Gitler AD, Cashikar AG et al.

    Nature genetics 2009;41;3;316-23

  • Skeletal muscle gene expression profiling in mitochondrial disorders.

    Crimi M, Bordoni A, Menozzi G, Riva L, Fortunato F et al.

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2005;19;7;866-8

  • Over-representation of exonic splicing enhancers in human intronless genes suggests multiple functions in mRNA processing.

    Pozzoli U, Riva L, Menozzi G, Cagliani R, Comi GP et al.

    Biochemical and biophysical research communications 2004;322;2;470-6

  • Effects of reboxetine on sleep and nocturnal cardiac autonomic activity in patients with dysthymia.

    Ferini-Strambi L, Manconi M, Castronovo V, Riva L and Bianchi A

    Journal of psychopharmacology (Oxford, England) 2004;18;3;417-22

  • A locus on 15q15-15qter influences dyslexia: further support from a transmission/disequilibrium study in an Italian speaking population.

    Marino C, Giorda R, Vanzin L, Nobile M, Lorusso ML et al.

    Journal of medical genetics 2004;41;1;42-6

  • Silencer elements as possible inhibitors of pseudoexon splicing.

    Sironi M, Menozzi G, Riva L, Cagliani R, Comi GP et al.

    Nucleic acids research 2004;32;5;1783-91

  • Comparative analysis of vertebrate dystrophin loci indicate intron gigantism as a common feature.

    Pozzoli U, Elgar G, Cagliani R, Riva L, Comi GP et al.

    Genome research 2003;13;5;764-72

Riva, Laura
Laura's Timeline
2017

Wellcome Trust Sanger Institute

2012

Team leader, CGS@SEMM at the Instituto Italiano di Tecnologia, Milan

2010

AIRC/Marie Curie International Fellowship in Cancer Research

Postdoctoral fellow, European Institute of Oncology, Milan

2007

Postdoctoral fellow MIT

PhD in Bioengineering Politecnico di Milano

2006

Visiting student MIT, supported by Progetto Rocca MIT-PoliMi Program